Idiopathic pulmonary fi brosis: New evidence and an improved standard of care in 2012

The Lancet

Volumn 380, Issue 9842, 2012, Pages 699-701

  Raghu, Ganesh ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; ANTICOAGULANT AGENT; AZATHIOPRINE; BOSENTAN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GAMMA1B INTERFERON; PIRFENIDONE; PREDNISONE; SILDENAFIL; WARFARIN;

CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; OXYGEN THERAPY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SHORT SURVEY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ARTICLE; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; METHODOLOGY; STANDARD; TOTAL QUALITY MANAGEMENT;

EVIDENCE-BASED MEDICINE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PRACTICE GUIDELINES AS TOPIC; QUALITY IMPROVEMENT; STANDARD OF CARE;

EID: 84865132003     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61256-2     Document Type: Note

References (25)

1. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fi brosis: diagnosis and treatment-international consensus statement. Am J Respir Crit Care Med 2000; 161: 646-64.
2. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fi brosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-96.
3. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fi brosis. N Engl J Med 2005; 353: 2229-42.
4. Raghu G, Collard HR, Egan JJ, for the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An offi cial ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fi brosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
5. Schünemann HJ, Jaeschke R, Cook DJ, et al, for the ATS Documents Development and Implementation Committee. An offi cial ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006; 174: 605-14.
6. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FA, Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fi brosis. N Engl J Med 2012; 366: 1968-77.
7. Noth I, Anstrom KJ, Calvert SB, et al, for the Idiopathic Pulmonary Fibrosis Clinical Research Network. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2012; 186: 88-95.
8. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fi brosis. Chest 2005; 128: 1475-82.
9. Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fi brosis. N Engl J Med 2010; 363: 620-28.
10. Raghu G, Behr J, Brown K, et al. Artemis-IPF: a placebo-controlled trial of ambrisentan in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2012; 185: A3632.
11. King T, Behr J, Brown K, et al. BUILD 1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2008; 177: 75-81.
12. King T, Brown K, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2011; 184: 92-99.
13. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J. Effi cacy and safety of macitentan in idiopathic pulmonary fi brosis: results of a prospective, randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2012; 185: A3631.
14. Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fi brosis. N Engl J Med 2005; 353: 2285-87.
15. Raghu G, Brown K, Bradford W, et al, for the Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fi brosis. N Engl J Med 2004; 350: 125-33.
16. Raghu G, Brown K, Costabel U, et al. Treatment of idiopathic pulmonary fi brosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178: 948-55.
17. Noble P, Albera C, Bradford W, et al. Pirfenidone in patients with idiopathic pulmonary fi brosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-69.
18. Richeldi L, Costabel U, Selman M, et al. Effi cacy of a tyrosine kinase inhibitor in idiopathic pulmonary fi brosis. N Engl J Med 2011; 365: 1079-87.
19. King TE Jr, Albera C, Bradford WZ, et al, for the INSPIRE Study Group. Eff ect of interferon gamma-1b on survival in patients with idiopathic pulmonary fi brosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-28.
20. Lee J, Ryu J, Elicker B, et al. Gastroesophageal refl ux therapy is associated with longer survival in patients with idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2011; 184: 1390-94.
21. Raghu G. Idiopathic pulmonary fi brosis: increased survival with "gastroesophageal refl ux therapy": fact or fallacy? Am J Respir Crit Care Med 2011; 184: 1330-32.
22. Noth I, Zangan S, Soares R, et al. Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fi brosis. Eur Respir J 2012; 39: 344-51.
23. Lee JS, Song JW, Wolters PJ, et al .Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fi brosis. Eur Respir J 2012; 39: 352-58.
24. Raghu G, Meyer K. Silent gastro-esophageal refl ux and microaspiration in IPF: mounting evidence for anti-refl ux therapy? Eur Respir J 2012; 39: 242-45.
25. Raghu G ,Collard H, Anstrom K, et al. Idiopathic pulmonary fi brosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185: 1044-48.